Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Becker, Joergen C.; Ugurel, Selma; Leiter, Ulrike; Meier, Friedegund; Gutzmer, Ralf; Haferkamp, Sebastian; Zimmer, Lisa; Livingstone, Elisabeth; Eigentler, Thomas K.; Hauschild, Axel; Kiecker, Felix; Hassel, Jessica C.; Mohr, Peter; Fluck, Michael; Thomas, Ioannis; Garzarolli, Marlene; Grimmelmann, Imke; Drexler, Konstantin; Spillner, Alexandra N.; Eckhardt, Sebastian; Schadendorf, Dirk

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Autor(en):

Becker, Joergen C.; Ugurel, Selma; Leiter, Ulrike; Meier, Friedegund; Gutzmer, Ralf; Haferkamp, Sebastian; Zimmer, Lisa; Livingstone, Elisabeth; Eigentler, Thomas K.; Hauschild, Axel; Kiecker, Felix; Hassel, Jessica C.; Mohr, Peter; Fluck, Michael; Thomas, Ioannis; Garzarolli, Marlene; Grimmelmann, Imke; Drexler, Konstantin; Spillner, Alexandra N.; Eckhardt, Sebastian; Schadendorf, Dirk

Tübinger Autor(en):

Thomas, Ioannis
Leiter-Stöppke, Ulrike
Eigentler, Thomas

Erschienen in:

Lancet (2023), Bd. 402, H. 10404, S. 798-808

Verlagsangabe:

New York : Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S0140-6736(23)00769-9

ISSN:

0140-6736